Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2012Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 967Neoplasm Metastasis 902Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Lymphoma, Non-Hodgkin 659Prostatic Neoplasms 657Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 486Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 387Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 357Lymphoma, Mantle-Cell 345Glioma 343

Interventions

Radiotherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy × Clear all
NCT02207465 2025-11-19

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
42 enrolled
Gastrointestinal

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡